|
|
Previous Article | Table of Contents | Next Article 
Regression of experimental Burkitt's lymphoma induced by Epstein-Barr
virus-immortalized human B cells
G Tosato, C Sgadari, K Taga, KD Jones, SE Pike, A Rosenberg, JM Sechler, IT Magrath, LA Love and K Bhatia
Division of Hematologic Products, Center for Biologics Evaluation and
Research, Rockville, MD 20852-1448.
Epstein-Barr virus (EBV)-immortalized human B cells survive only
transiently when injected subcutaneously into athymic mice, whereas
Burkitt's lymphoma cells give rise to progressively growing subcutaneous
tumors. In this study, we tested whether these Burkitt's tumors could be
induced to regress via a bystander effect induced by EBV-immortalized B
cells. Simultaneous inoculation of EBV-immortalized B cells and Burkitt's
lymphoma cells in the same subcutaneous site resulted in tumors that
regressed with necrosis and scarring. Similarly, simultaneous inoculation
of EBV-immortalized B cells and Burkitt's lymphoma cells in separate
subcutaneous sites resulted in regression of a proportion of the Burkitt's
tumors. Furthermore, most of the established human Burkitt's tumors
regressed with necrosis and scarring after intratumor inoculations with
EBV-immortalized B cells. The EBV-immortalized B cells continued to exert
this antitumor effect even when killed with irradiation. The experimental
approach to Burkitt's lymphoma treatment described here exploits the
ability of athymic mice to reject EBV-immortalized B cells to target an
effective antitumor response to malignant cells normally incapable of
eliciting it.
Volume 83,
Issue 3,
pp. 776-784,
02/01/1994
Copyright © 1994 by The American Society of Hematology

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
B. P. O'Neill, S. Vernino, A. Dogan, and C. Giannini
EBV-associated lymphoproliferative disorder of CNS associated with the use of mycophenolate mofetil
Neuro-oncol,
July 1, 2007;
9(3):
364 - 369.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Yao, J. Setsuda, C. Sgadari, B. Cherney, and G. Tosato
Interleukin-18 expression induced by Epstein-Barr virus-infected cells
J. Leukoc. Biol.,
May 1, 2001;
69(5):
779 - 784.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
L. Guedez, A. J. McMarlin, D. W. Kingma, T. A. Bennett, M. Stetler-Stevenson, and W. G. Stetler-Stevenson
Tissue Inhibitor of Metalloproteinase-1 Alters the Tumorigenicity of Burkitt's Lymphoma via Divergent Effects on Tumor Growth and Angiogenesis
Am. J. Pathol.,
April 1, 2001;
158(4):
1207 - 1215.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Yao, S. E. Pike, J. Setsuda, J. Parekh, G. Gupta, M. Raffeld, E. S. Jaffe, and G. Tosato
Effective targeting of tumor vasculature by the angiogenesis inhibitors vasostatin and interleukin-12
Blood,
September 1, 2000;
96(5):
1900 - 1905.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L.-M. Ching, D. Goldsmith, W. R. Joseph, H. Korner, J. D. Sedgwick, and B. C. Baguley
Induction of Intratumoral Tumor Necrosis Factor (TNF) Synthesis and Hemorrhagic Necrosis by 5,6-Dimethylxanthenone-4-Acetic Acid (DMXAA) in TNF Knockout Mice
Cancer Res.,
July 1, 1999;
59(14):
3304 - 3307.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Setsuda, J. Teruya-Feldstein, N. L. Harris, J. A. Ferry, L. Sorbara, G. Gupta, E. S. Jaffe, and G. Tosato
Interleukin-18, Interferon-{gamma}, IP-10, and Mig Expression in Epstein-Barr Virus-Induced Infectious Mononucleosis and Posttransplant Lymphoproliferative Disease
Am. J. Pathol.,
July 1, 1999;
155(1):
257 - 265.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Yao, C. Sgadari, K. Furuke, E. T. Bloom, J. Teruya-Feldstein, and G. Tosato
Contribution of Natural Killer Cells to Inhibition of Angiogenesis by Interleukin-12
Blood,
March 1, 1999;
93(5):
1612 - 1621.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. E. Pike, L. Yao, K. D. Jones, B. Cherney, E. Appella, K. Sakaguchi, H. Nakhasi, J. Teruya-Feldstein, P. Wirth, G. Gupta, et al.
Vasostatin, a Calreticulin Fragment, Inhibits Angiogenesis and Suppresses Tumor Growth
J. Exp. Med.,
December 21, 1998;
188(12):
2349 - 2356.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Soto, W. Wang, R. M. Strieter, N. G. Copeland, D. J. Gilbert, N. A. Jenkins, J. Hedrick, and A. Zlotnik
The CC chemokine 6Ckine binds the CXC chemokine receptor CXCR3
PNAS,
July 7, 1998;
95(14):
8205 - 8210.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. W. Cherney, C. Sgadari, C. Kanegane, F. Wang, and G. Tosato
Expression of the Epstein-Barr Virus Protein LMP1 Mediates Tumor Regression In Vivo
Blood,
April 1, 1998;
91(7):
2491 - 2500.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Teruya-Feldstein, E. S. Jaffe, P. R. Burd, H. Kanegane, D. W. Kingma, W. H. Wilson, D. L. Longo, and G. Tosato
The Role of Mig, the Monokine Induced by Interferon-gamma , and IP-10, the Interferon-gamma -Inducible Protein-10, in Tissue Necrosis and Vascular Damage Associated With Epstein-Barr Virus-Positive Lymphoproliferative Disease
Blood,
November 15, 1997;
90(10):
4099 - 4105.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Sgadari, J. M. Farber, A. L. Angiolillo, F. Liao, J. Teruya-Feldstein, P. R. Burd, L. Yao, G. Gupta, C. Kanegane, and G. Tosato
Mig, the Monokine Induced By Interferon-gamma , Promotes Tumor Necrosis In Vivo
Blood,
April 15, 1997;
89(8):
2635 - 2643.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Sgadari, A. L. Angiolillo, B. W. Cherney, S. E. Pike, J. M. Farber, L. G. Koniaris, P. Vanguri, P. R. Burd, N. Sheikh, G. Gupta, et al.
Interferon-inducible protein-10 identified as a mediator of tumor necrosis in vivo
PNAS,
November 26, 1996;
93(24):
13791 - 13796.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|
|